• Experimental immunotherapy modelled on PD-1 treatment to be tested in advanced melanoma patients
Michael Olugbode in Abuja
Cuban scientists have reached a potentially significant milestone in the country’s long-running effort to develop home-grown cancer treatments, with an experimental drug known as 2C12 ready to enter clinical testing in patients suffering from advanced melanoma.
The drug was developed by researchers at Cuba’s Centre for Molecular Immunology (CIM). It was designed around an approach similar to that used by pembrolizumab, an established immune-checkpoint therapy used internationally against several cancers, including unresectable or metastatic melanoma.
The development is attracting attention because 2C12 is moving beyond laboratory research towards testing in human beings — the stage at which its safety, tolerability, and potential therapeutic benefit must be established before any claim can be made about its effectiveness.
According to information released by CIM and subsequently reported by Cuban and international media, the initial clinical study will target patients with advanced melanoma that cannot be removed surgically or has spread to other parts of the body. The study will involve specialist oncology centres in Havana and Villa Clara.
The participating institutions include Cuba’s National Institute of Oncology and Radiobiology and Hermanos Ameijeiras Clinical Surgical Hospital in Havana, as well as the Dr. Celestino Hernández Robau Territorial University Oncology Hospital in Villa Clara.
The significance of the Cuban project extends beyond the development of another cancer medicine.
Cancer treatment has become an increasingly sophisticated but expensive field, with access to modern therapies varying sharply between countries.
World Health Organisation (WHO) said cancer caused nearly 10 million deaths worldwide in 2024, making it one of the leading causes of death globally.
It also warns of major inequalities in access to cancer prevention, diagnosis, and treatment between countries and income groups.
For Cuba, the challenge has an additional dimension. The country said difficulties obtaining some imported medicines, together with the high international cost of oncology products, had strengthened the case for developing domestic alternatives.
That backdrop has made biotechnology and pharmaceutical self-reliance a strategic priority for Cuban scientists.
CIM has consequently positioned 2C12 as a potential locally produced alternative to expensive imported immunotherapy. But the scientific test is now much tougher: the molecule must demonstrate in clinical trials that it is safe and actually benefits patients.
Pembrolizumab, the drug to which 2C12 has been compared, belongs to a class of medicines known as PD-1 inhibitors.
PD-1 is a receptor involved in regulating the immune system. Tumours can exploit this pathway to suppress immune responses, effectively helping cancer cells evade attack. Blocking the PD-1 pathway can restore part of the immune system’s ability to recognise and fight malignant cells.
The US Food and Drug Administration currently lists pembrolizumab as a PD-1-blocking antibody indicated for patients with unresectable or metastatic melanoma, among other cancers.
That makes the Cuban approach scientifically significant, but the similarity does not mean 2C12 has already been shown to work as well as pembrolizumab.
The Cuban molecule remains an investigational candidate. Its performance will have to be established through properly conducted clinical research.
Melanoma develops from melanocytes, the cells responsible for producing the pigment melanin. Although melanoma accounts for only a small proportion of skin cancers, it can be particularly aggressive and can spread to distant organs when diagnosis and treatment are delayed.
The FDA described unresectable or metastatic melanoma as an aggressive disease that can be fatal and notes that modern treatment can include PD-1 immunotherapy and targeted treatment for patients whose tumours carry particular BRAF mutations.
The treatment landscape is also continuing to evolve. In August 2026, the FDA granted accelerated approval to another therapy, the genetically modified Oncolytic virus Vusolimogene Oderparepvec, in combination with nivolumab for certain patients with advanced melanoma whose disease has progressed after PD-1-based treatment.
The developments underline the intensity of the global race to find more effective options for patients whose cancers stop responding to existing therapies.
For Cuban researchers, 2C12 could eventually represent an important achievement in pharmaceutical independence. For patients, however, the immediate significance should be viewed with measured optimism.
The drug has not been established as a cure for cancer, nor has it yet been demonstrated to be equivalent to pembrolizumab.
Researchers will need to determine how well patients tolerate the treatment, what adverse effects occur, whether the drug produces measurable tumour responses and how durable any responses may be.
Larger and more rigorous studies would then be needed to establish its effectiveness and place in cancer treatment.
That distinction is crucial because promising laboratory candidates frequently fail to become successful medicines once tested in humans.
The Cuban development also carries a broader message for countries, including Nigeria, that continue to rely heavily on imported medicines and medical technologies.
Developing a cancer drug requires far more than discovering a molecule. It demands scientific expertise, biotechnology infrastructure, clinical research capacity, regulatory oversight, pharmaceutical manufacturing and sustained financing.
Nigeria has a large and growing cancer burden, while access to sophisticated oncology services remains uneven.
WHO has emphasised that major disparities persist globally in access to cancer care, particularly across countries with different levels of health-system resources.
Cuba’s 2C12 project therefore offers an example of how investment in domestic scientific capacity can potentially be translated into locally developed medical products.
For now, 2C12 is best understood as a Cuban cancer-treatment candidate entering an important clinical-testing phase — not a proven cure.
If the trials establish that it is safe, effective and capable of producing meaningful benefits for patients, the development could mark a major step in Cuba’s biotechnology programme and potentially add another weapon to the global fight against advanced cancer.
For millions of cancer patients watching the worldwide search for more affordable and effective treatments, that is a development worth following closely.